ArticleHemodialysis international. International Symposium on Home Hemodialysis2026
Extended Double Plasma Molecular Adsorption Sessions and Bilirubin Clearance: A Case Report.
Article in Hemodialysis international. International Symposium on Home Hemodialysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe double plasma molecular adsorption system is an artificial-liver treatment model combining the use of ion exchange resins and neutral microporous resins to remove toxins such as inflammatory cytokines without consuming large amounts of plasma and albumin. Given the relatively expensive consumables needed for Bilirubin adsorption, extending treatment duration and maximizing adsorption column efficiency help save medical expenses and resources. CASE PRESENTATION: We report on a 51-year-old male hyperbilirubinemia patient of Chinese Han ethnicity, which was treated with prolonged double plasma molecular adsorption system sessions. The patient underwent two treatment sessions, each lasting over 6 h with a plasma adsorption volume greater than 10 L. total bilirubin clearance was 44.6% in the first session and 34.6% in the second. Dynamic monitoring of serum total bilirubin showed that clearance was maximized when plasma adsorption volume equaled the patient's plasma volume. When plasma adsorption volume reached 2 × plasma volume, total bilirubin decreased by less than 20%, indicating near-saturation of the column's bilirubin adsorption capacity. After plasma adsorption volume doubled in the first session, total bilirubin clearance dropped to nearly 20%, suggesting that the column still had some adsorption capacity. While the efficiency of bilirubin removal per unit of plasma volume decreased, continuing the treatment still allowed for the elimination of additional bilirubin.
conclusionTotal plasma adsorption volume in a single double plasma molecular adsorption system treatment session can serve as a reference for determining the therapeutic dose in future treatments. Furthermore, extending the treatment duration with a bilirubin adsorption column enhances bilirubin clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.